Skip to content

Abstract 7932: Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score

Nov 2026 · Circulation · 0 citations

Abstract

Background: The prespecified FIDELITY analysis of two phase 3 trials found that finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD); however, the magnitude of benefit in patients without prior CV disease (CVD) has not been characterized. The American Heart Association (AHA) Predicting Risk of cardiovascular disease EVENTs (PREVENT™) equations estimate 10-year CVD risk using a base model of clinical and hemodynamic characteristics and a full model that includes additional factors, such as the urinary albumin-to-creatinine ratio (UACR) and glycated hemoglobin, adapted to a T2D and CKD population. Research Question: Is the impact of finerenone on cardiovascular risk in patients with type 2 diabetes and chronic kidney disease, without a history of cardiovascular disease, influenced by the baseline PREVENT™ score? Does finerenone treatment mitigate the progression of the longitudinal score? Methods: In this post hoc analysis of the FIDELITY dataset, we stratified patients into tertiles of baseline PREVENT™ score (low/intermediate/high risk; base and full models) and calculated hazard ratios (HRs) using a Cox proportional hazards model for time to first non-fatal CV event. Treatment effect heterogeneity between tertiles was assessed via the interaction p -value. We calculated cumulative incidence and the number needed to treat (NNT) at 3 years for the time to first occurrence of a non-fatal CV event, based on Aalen-Johansen estimates. The change in PREVENT™ score up to Month 48 was analyzed using a linear mixed-effects model. Results: In total, 7050 patients without prior CVD were included (3519 finerenone; 3531 placebo). The effect of finerenone on non-fatal CV events was consistent across baseline PREVENT™ tertiles (Figure 1; base model low tertile HR [95% confidence interval] was 0.89 [0.60-1.32], intermediate 1.11 [0.79-1.56], high 0.85 [0.65-1.11]; p interaction 0.57 [base model] and 0.41 [full model]). Absolute benefit increased with baseline risk with lowest 3-year NNT seen in the high-risk tertile (28 patients, full model; Figure 2). Finerenone significantly reduced the progression of PREVENT™ score relative to placebo at Month 48 using the base model (least squares mean difference -0.018; p<0.01) and from Month 4 using the full model (p<0.0001; Figure 3). Conclusion: Finerenone demonstrated consistent CV benefit across AHA PREVENT™-estimated risk levels. The most significant absolute benefit and lowest NNT were observed in the highest risk tertile, supporting risk-based identification of individuals most likely to benefit. Finerenone also significantly decelerated longitudinal PREVENT™ score progression, with its greater effect in the comprehensive model including UACR supporting albuminuria reduction as a key mechanistic mediator of its disease modifying effects.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.